Prognostic Indicators in Hepatocellular Carcinoma (HCC) in a Moroccan Population

Article Information

Nada Lahmidani*, Fatime Zahra Hamdoun, Hakima Abid, Maria.Lahlali, Mohammed El Abkari, Sidi Adil Ibrahimi

Department of Gastroenterology, University Hospital Hassan II, School of Medicine and Pharmacy of Fez, Sidi Mohammed Ben Abdallah University, Fez, Morocco

*Corresponding Author: Prof. Nada Lahmidani, Department of Gastroenterology, University Hospital Hassan II, School of Medicine and Pharmacy of Fez, Sidi Mohammed Ben Abdallah University, Fez, Morocco

Received: 02 April 2020; Accepted: 17 April 2020; Published: 27 April 2020

Citation: Nada Lahmidani, Fatime Zahra Hamdoun, Hakima Abid, Maria.Lahlali, Mohammed El Abkari, Sidi Adil Ibrahimi. Prognostic Indicators in Hepatocellular Carcinoma (HCC) in a Moroccan Population. Journal of Cancer Science and Clinical Therapeutics 4 (2020): 115-119.

View / Download Pdf Share at Facebook


Prognostic Indicators in Hepatocellular Carcinoma (HCC) in a Moroccan Population


Hepatocellular carcinoma; Prognostic indicators; Poor prognosis

Hepatocellular carcinoma articles, Prognostic indicators articles, Poor prognosis articles

Article Details

1. Introduction

HCC is the most common primary liver tumor with a high mortality rate. It is an unpredictable cancer with unpredictable progression. Worldwide, it is the fifth most common type of cancer and third most common cause of cancer mortality [1]. Screening ultrasound plays an essential role in cirrhotic patients; it increases the percentage of HCC detection at an early stage and consequently opens up the possibility of curative treatment [2]. The various forms of treatment available for these tumours are effective in improving survival only when the disease is diagnosed at an early stage. For patients with larger tumours and decompensated cirrhosis, no treatment appears to be capable of prolonging survival [3]. The prognosis for HCC on cirrhosis is generally poor and seems to be determined not only by factors linked to the tumor, but also by factors linked to cirrhosis. The main objective of our study is to determine prognostic factors in cirrhotic patients with HCC.

2. Methods

This is a retrospective study of patients with hepatocellular carcinoma on cirrhosis liver diagnosed from January 2009 to July 2019. The diagnosis of HCC was made according to the non-invasive criteria of EASL (existence of a hypervascularized nodule at early arterial time (wash-in) with washing (wash-out: hypodensity or hypointensity compared to the non-tumoral hepatic parenchyma) in the portal phase or in the late phase compared to the non-tumorous parenchyma tumor) with the use of histology for doubtful cases. The degree of hepatocellular insufficiency was defined by the CHILD score. The response to treatment was evaluated at 1 month then 3 months for per cutaneous treatment, 3 months for hepatic resection and Sorafenib and according to the RECIST criteria for transarterial chemoembolization (Complete response if complete disappearance of the enhancement of the treated area, partial response if reduction >50% of the viable part of the target lesion, progression if increase  >25% of the viable part of the target lesion or new lesion, stability in other cases).

3. Statistical Analysis

The results were analyzed using the Statistics Package for Social Science software (SPSS version 20) for Windows. Quantitative variables were expressed as average ± standard deviation. Qualitative variables were expressed in number and percentage (%). Multivariate analysis was performed with a binary logistic regression model to identify prognostic factors and we considered significant a p≤0.05. Survival data was analyzed by Kaplan Meier method.

4. Results

We have collected 148 cases of HCC on cirrhosis liver. The average age was 64 [18; 72] years predominance of female. The etiology of cirrhosis was secondary to the hepatitis B and C virus in 79.7%. Child's score was ≥ B7 in 35.8%. Alpha fetoprotein (AFP) exceeded >400 ng/ml in 28.3%. HCC nodules exceeded 3 cm in 66.9%. Invasion of the portal vein was objectified in 15.9% with the presence of metastases in 19%. Only 22.9% patients had curative treatment: 14.86% received per cutaneous treatment and 8.1% had liver resection. Palliative means interested 77% of patients: Transarterial chemoembolization in 39.18%, Sorafenib was used in 22.97% and 13.5% were beyond all therapeutic resources (Table 1). The evolution was marked by progression in 61%. The average overall survival at 1 year and at 5 years was 68.7% and 27% respectively. We noted a significant reduction in survival rate at 1 year: it has decreased from 86, 2% to less than 27% at 5 years which supports the prognosis for CHC (Figure1). The prognostic indicators of death were respectively advanced child (p=0.005), AFP level >400 ng/ml (p=0.02) and presence of metastasis (p <0.001) Table 2.

middle age

64 [18; 72] ans

Sexe ratio (F/H)


Cirrhosis etiology



metabolic syndrome

53.37% (N 79)

26.35% (N 39)

20.27% (N 30)


68% (N 101)

Who score



85% (N 126)

14.86% (N 22)

AFP score

≤10 ng/ml

 >10  ng/ml et ≤ 400 ng/ml

 >400 ng/ml

34.45% (N 51)

37.16% (N 55)

28.3% (N 42)

CHILD score

Child  A

Child B/C

64.18% (N 95)

35.8% (N 53)

Characteristic of the tumor:

Small CHC (<3 cm)

Portal vein thrombosis


33.1% (N 49)

14.8%(N 22)

17% (N 25)

Curative treatment


Alcohol ablation

Liver resection

6.08% (N 9)

8.78% (N 13)

8.10% (N 12)

Other therapeutic means

transarterial chemoembolization


Symptomatic treatment

39.18% (N 58)

22.97% (N 34)

13.5% (N 20)

Table 1: Characteristics of the studied population.

Prognostic factors



Confidence interval

Child avanced



[1,36; 6,05]

AFP level >400 ng / ml



[1,15; 4,77]

Presence of metastasis



[1,13; 4,04]

Portal vein thrombosis



[0,86; 8,83]

Table 2: Poor prognostic factors in patients with HCC on cirrhosis liver.



Figure 1: Survival curve for patients with HCC on cirrhosis liver.

5. Discussion

Prognostic studies in HCC are often unsatisfactory because patients included are heterogeneous. Tumor staging at the time of diagnosis is essential to decide which type of therapy is the most appropriate for patients. Several alternative staging systems have been proposed. The CLIP studies identified five independent prognostic variables: Child-Pugh class of cirrhosis, tumour size, number of lesions, presence/absence of portal vein thrombosis, and serum levels of AFP [4]. The Okuda system is a prognostic score introduced in 1985; it includes the tumor volume, the presence of ascites, and the levels of serum albumin and bilirubin [5].

The Barcelona Clinic Liver Cancer (BCLC) staging classification includes four stages: Early stage (A) for patients with asymptomatic early tumors suitable for radical therapies, intermediate stage (B) comprises patients with asymptomatic multinodular HCC. Advanced stage (C) includes patients with symptomatic tumors and/or an invasive tumoral pattern, end-stage disease (D) contains patients with extremely grim prognosis that should merely receive symptomatic treatment [6].

Our finding of the prognostic indicators of death were the advanced child, AFP level >400 ng/ml, presence of metastases and invasion of the portal vein which joins Tandon et al.  [7], these have shown in addition to the above described prognostic indicators that the clip score is also predictors of death. Grieco A et al. [8] founded that portal vein thrombosis; alpha fetoprotein, total bilirubin, and tumor size were significant predictors of survival. Okuda, CLIP, and BCLC scores were all able to predict survival (p=0.001). They identified two, four, and six risk groups, respectively, with a median survival ranging from 27 to 19 months for Okuda, 30 to 5 months for CLIP, and 43 to 7 months for BCLC. According to Marrero et al.  [9], the independent predictors of survival were performance status (P < .0001), MELD score greater than 10 (P=0.001), portal vein thrombosis (P=0.0001), and tumor diameter greater than 4 cm (P=0.001). The Barcelona Clinic Liver Cancer (BCLC) staging system had the best independent predictive power for survival when compared with the others prognostic systems.

The future in terms of predictor factors of survival in HCC will certainly go towards the study of molecular phenotypes this is what has shown Calderaro J et al. [10] who concluded that HCC phenotype is tightly associated to its molecular alterations and underlying oncogenic pathways. The study evoked a novel subtype of HCC, designated as "macrotrabecular-massive" associated with poor survival (p<0.001), high alpha foeto-protein serum level (P=0.02), vascular invasion (P<0.001), TP53 mutations (P<0.001) and FGE 19 (P=0.02).

6. Conclusion

Hepatocellular carcinoma remains a tumor with a poor prognosis. The prognostic indicators of death, in our study, were respectively the advanced Child, the rate of AFP >400 ng/ml, the presence of metastases and invasion of the portal vein. Our results should be confirmed in a larger multicenter cohort to study the effect of multiple etiologies, ethnicity, and the effect of various treatments on overall survival. A consensus in prognostic staging for HCC is urgently needed to assure progress in the development of biomarkers for early detection and novel therapies.

Conflict of Interests

All authors agree with the content of the manuscript and there are no conflicts of interests between them.


No financial funding.


  1. Golabi P, et al. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore) 96 (2017): e5904.
  2. Solmi L, Primerano AM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol 91 (1996): 1189-1194.
  3. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 51 (2002): 459-462.
  4. The Cancer of Liver Italian Program (CLIP) Investigation. Prospective validation of the CLIP score: a new prognostic system for patients with hepatocellular carcinoma. Hepatology 31 (2000): 840-845.
  5. Dilou N, et al. Hepatocellular carcinoma survival prediction classifications. Gastroenterol clin biol 28 (2004): 359-366.
  6. Llovet JM, Bru` C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLCstaging classification. Semin Liver Dis 19 (1999): 329-338.
  7. Tandon GT, et al. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver International (2009): 1478-3223.
  8. Grieco A, et al. Prognostic factors for survival in patients with earlyintermediate hepatocellular carcinoma undergoing nonsurgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54 (2005): 411-418.
  9. Marrero et al. Prognosis of Hepatocellular Carcinoma: Comparison of 7 Staging Systems in an American Cohort. Hepatology (2005).
  10. Calderaro J, et al. Histological Subtypes of Hepatocellular Carcinoma Are Related To Gene Mutations and Molecular Tumour Classification. J Hepatol (2017).

© 2016-2023, Copyrights Fortune Journals. All Rights Reserved